Dr. Maria Restrepo MD

Recommended Articles

• Astonishing Clinical Trial Results Show Promise for Non-Hodgkin Lymphoma Research

  There’s good news for those who’ve been diagnosed with the aggressive non-Hodgkin lymphoma (NHL) type referred to as diffuse large-B cell (DLBCL). According to the American Cancer Society (ACS), this type of HNL is the most common type of lymphoma.The descriptive letters clarify the type of...

• What Specialists Treat Multiple Myeloma?

  If you suffer from multiple myeloma, which a rare form of blood cancer, one of the most crucial decisions you will have to make is choosing a doctor who specializes in multiple myeloma. A hematologist-oncologist is the specialist you need who will manage your cancer throughout the cycle of...

• Tips on How to Live with Multiple Myeloma

  Multiple myeloma, a type of cancer, adversely affects plasma cells, which are your immune system’s components. The American Cancer Society indicates that in 2014, more than 24,000 people in the United States had multiple myeloma.Multiple myeloma patients can lose their appetite due to the adverse...

• How Immunotherapy Makes a Real Difference in Relapsed Hodgkin Lymphoma

  Hodgkin lymphoma, which affects about 0.2% of the people in the United States, is often treated using a combination of chemotherapy, radiation therapy, and stem cell transplant. Sometimes these treatments fail to halt the progress of the disease, and in other cases the cancer seems to halt but then...

• The Lymphoma Research Foundation's Light it Red for Lymphoma Night

  Lymphoma, a cancer of the lymphatic system, currently affects over 700,000 Americans who are living with or in remission from the disease. Statistics show that every seven minutes, someone in the United States is diagnosed with the condition, which amounts to approximately 80,000 people per year.The...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...